These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 18378533)

  • 21. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients.
    Vadaparampil ST; Quinn GP; Miree CA; Brzosowicz J; Carter B; Laronga C
    Ann Surg Oncol; 2009 Jul; 16(7):1973-81. PubMed ID: 19408048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort.
    Fortuny D; Balmaña J; Graña B; Torres A; Ramón y Cajal T; Darder E; Gadea N; Velasco A; López C; Sanz J; Alonso C; Brunet J
    Hum Reprod; 2009 Apr; 24(4):1000-6. PubMed ID: 19112076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unknown significance.
    Couzin-Frankel J
    Science; 2014 Dec; 346(6214):1167-70. PubMed ID: 25477439
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetic evaluation of cancer: the importance of family history.
    Chew HK
    Tex Med; 2001 Feb; 97(2):40-5. PubMed ID: 11233057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethical issues related to BRCA gene testing in orthodox Jewish women.
    Mor P; Oberle K
    Nurs Ethics; 2008 Jul; 15(4):512-22. PubMed ID: 18515440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perceptions of genetic testing for cancer predisposition among Ashkenazi Jewish women.
    Lewis MJ; Peterson SK
    Community Genet; 2007; 10(2):72-81. PubMed ID: 17380056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.
    Matloff ET; Shappell H; Brierley K; Bernhardt BA; McKinnon W; Peshkin BN
    J Clin Oncol; 2000 Jun; 18(12):2484-92. PubMed ID: 10856109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Identification of cancer genes has made the testing of predisposition possible. Genetic counseling and mutation screening can result in new therapeutic methods].
    Nordenskjöld M
    Lakartidningen; 1999 Aug; 96(32-33):3392-6. PubMed ID: 10479788
    [No Abstract]   [Full Text] [Related]  

  • 29. Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Eur J Cancer; 2007 Jan; 43(1):71-7. PubMed ID: 17045473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary breast and ovarian cancer syndrome: should we test adolescents?
    Seeber B; Driscoll DA
    J Pediatr Adolesc Gynecol; 2004 Jun; 17(3):161-7. PubMed ID: 15125901
    [No Abstract]   [Full Text] [Related]  

  • 31. Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk.
    Wakefield CE; Meiser B; Homewood J; Ward R; O'Donnell S; Kirk J;
    Cancer; 2008 Sep; 113(5):956-65. PubMed ID: 18618513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk.
    Wakefield CE; Meiser B; Homewood J; Peate M; Taylor A; Lobb E; Kirk J; Young MA; Williams R; Dudding T; Tucker K;
    Breast Cancer Res Treat; 2008 Jan; 107(2):289-301. PubMed ID: 17333332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk communication strategies: state of the art and effectiveness in the context of cancer genetic services.
    Julian-Reynier C; Welkenhuysen M; Hagoel L; Decruyenaere M; Hopwood P;
    Eur J Hum Genet; 2003 Oct; 11(10):725-36. PubMed ID: 14512961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experiences from a clinic for patients with hereditary cancer. Diagnosis of genetic carriers may prevent cancer].
    Lindblom A; Iselius L
    Lakartidningen; 1995 May; 92(18):1915-8. PubMed ID: 7746044
    [No Abstract]   [Full Text] [Related]  

  • 35. The family covenant and genetic testing.
    Doukas DJ; Berg JW
    Am J Bioeth; 2001; 1(3):3-10. PubMed ID: 11954587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives].
    Christophe V; Leroy T; Adenis C; Reich M; Vennin P
    Bull Cancer; 2008 Apr; 95(4):395-402. PubMed ID: 18495568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life.
    Vos J; Otten W; van Asperen C; Jansen A; Menko F; Tibben A
    Psychooncology; 2008 Aug; 17(8):822-30. PubMed ID: 18157792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Maheu C; Thorne S
    Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing for cancer susceptibility genes in children.
    Laxova R
    Adv Pediatr; 1999; 46():1-40. PubMed ID: 10645460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Psychosocial factors associated with genetic testing for certain hereditary types of neoplasms].
    Franková V; Zidovská J; Krutílková V; Havlovicová M; Goetz P
    Cas Lek Cesk; 2003; 142(10):599-602. PubMed ID: 14635423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.